Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miteshkumar Solanki

Interventional Cardiology Powell, TN Medical Doctor

NPI 1093950081 CMS profile 231249

7557B Dannaher Dr Ste 225, Ste 225, Powell, TN 37849

Open in the dashboard

General payments

$11,118

208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miteshkumar Solanki of Powell, TN is reported in the CMS Open Payments database as having received $11,118 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $361 14
2024 General $893 15
2023 General $4,735 76
2022 General $3,265 52
2021 General $1,296 36
2020 General $192 10
2019 General $376 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miteshkumar Solanki
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Miteshkumar Solanki were reported at $361. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Miteshkumar Solanki Interventional Cardiology median Middle half National median
2019 $376 $1,097 $329–$3,048 $163
2020 $192 $473 $161–$1,480 $114
2021 $1,296 $677 $233–$1,827 $132
2022 $3,265 $978 $333–$2,724 $149
2023 $4,735 $1,136 $382–$2,986 $160
2024 $893 $1,181 $395–$3,326 $164
2025 $361 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,229 39 payments
  2. Edwards Lifesciences Corporation $1,546 17 payments
  3. Abbott Laboratories $1,487 35 payments
  4. Medtronic, Inc. $969 11 payments
  5. Terumo Medical Corporation $626 11 payments
  6. Penumbra, Inc. $608 4 payments
  7. Medtronic Vascular, Inc. $321 6 payments
  8. AstraZeneca Pharmaceuticals LP $300 6 payments
  9. Cardiovascular Systems Inc. $284 12 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $227 8 payments
  11. Other $1,520 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,725 187 payments
  2. Travel and Lodging $4,392 20 payments
  3. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. General - Vascular Access $1,215 4 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $951 16 payments
  3. COREVALVE EVOLUT R $912 8 payments
  4. VersaCross Access Solution $893 5 payments
  5. Indigo System $608 4 payments
  6. GLIDESHEATH SLENDER $392 5 payments
  7. DRAGONFLY OPSTAR $346 3 payments
  8. METACROSS OTW $285 5 payments
  9. COROFLOW $263 6 payments
  10. Resolute $234 3 payments
  11. Other $4,223 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,427

Median for Interventional Cardiology: 2,236

Drug cost

$239,947

Median for Interventional Cardiology: $380,412

Branded share of claims

32.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 106 $113,593
Xarelto Rivaroxaban Brand 58 $51,777
Entresto Sacubitril/Valsartan Brand 36 $35,269
Brilinta Ticagrelor Brand 38 $19,608
Farxiga Dapagliflozin Propanediol Brand 11 $6,445
Metoprolol Succinate Generic 191 $2,752
Ranolazine Er Ranolazine Brand 14 $1,651
Atorvastatin Calcium Generic 115 $1,260
Clopidogrel Clopidogrel Bisulfate Brand 106 $1,133
Potassium Chloride Generic 44 $760

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$70,396

Medicare's payments for the services billed

Medicare patients

393

Average age 75

Services billed

1,196

194 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Diabetes 48%
Arthritis 48%
Heart failure 47%
Atrial fibrillation 44%
Chronic kidney disease 44%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $68
$68 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $35
$35 106 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $35
$35 — —
Repatha
  • Amgen Inc. $20
$20 — —
VYNDAQEL
  • PFIZER INC. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record